Tirzepatide

Tirzepatide is a synthetic 39‑amino‑acid peptide that acts as a dual agonist at the GIP (glucose‑dependent insulinotropic polypeptide) and GLP‑1 (glucagon‑like peptide‑1) receptors, often called a “twincretin” Tirzepatide: First Approval+1. Developed by Eli Lilly, it received FDA approval in 2022 for type 2 diabetes and later for chronic weight management, making it the first approved dual GIP/GLP‑1 receptor agonist Tirzepatide: First Approval+1. A subsequent FDA approval extended its indication to moderate‑to‑severe obstructive sleep apnea in adults with obesity Tirzepatide (Zepbound) for obstructive sleep apnea+1.

By activating both incretin receptors, tirzepatide enhances insulin secretion when blood glucose is high, suppresses glucagon release, slows stomach emptying, and signals satiety, which together lower blood sugar and body weight Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus. In phase 3 trials for type 2 diabetes, once‑weekly doses of 5, 10, or 15 mg reduced HbA1c by roughly 2 percentage points versus placebo over 40 weeks, with weight losses of 6 – 9.7 kg Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). In obesity trials and meta‑analyses, tirzepatide 15 mg produced average placebo‑adjusted weight reductions near 18%, placing it among the most effective weight‑loss pharmacotherapies Comparative Effectiveness of <scp>CagriSegma</scp> , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials.

Real‑world evidence aligns with trial findings. One multicenter 6‑month study using low‑to‑moderate doses found that 94.2% of users achieved ≥5% weight loss and 77.9% achieved ≥10% Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study. Compared head‑to‑head with semaglutide, tirzepatide consistently shows greater weight loss—for example, 14.7% vs. 10.8% over two years in a propensity‑matched analysis Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study+1. Beyond glucose and weight, exploratory analyses from cardiovascular outcome trials suggest kidney protection: a 23% reduction in a composite kidney outcome versus dulaglutide over a median 4 years A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Cardiovascular benefit signals are favorable but less mature than for semaglutide; meta‑analyses report numerical reductions in major adverse cardiovascular events that do not yet reach statistical significance Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.

Additional lines of investigation include metabolic‑associated fatty liver disease, psoriasis with obesity, post‑bariatric weight regain, and use as adjunctive therapy in type 1 diabetes Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study+3. The most common side effects are gastrointestinal—nausea, constipation, diarrhea, and vomiting—which are most pronounced during dose escalation Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)+2. Rare but serious safety signals reported in post‑marketing data include hair loss, severe gastrointestinal dysmotility, ketoacidosis‑spectrum events, and bowel obstruction; these remain uncommon in absolute terms Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes+3.

Tirzepatide’s primary action is simultaneous activation of the GIP and GLP‑1 receptors, two related signaling pathways that normally amplify insulin release after meals and regulate appetite Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus+2. Because it engages both receptors, its effects on glucose control and weight are often larger than those seen with selective GLP‑1 agonists Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus+1.

At the pancreas, binding to beta‑cell receptors raises cyclic AMP, which increases insulin secretion when blood glucose is elevated. At the same time, it lowers inappropriate glucagon output from alpha cells. This dual action reduces both fasting and post‑meal glucose while keeping the risk of hypoglycemia low when tirzepatide is used alone Tirzepatide: First Approval+2.

In the gut and brain, GLP‑1 receptor engagement slows gastric emptying and promotes feelings of fullness. Combined GIP/GLP‑1 agonism further suppresses appetite and caloric intake through central nervous system signaling. Animal studies suggest GIP receptors in the lateral septum may reduce reward‑driven eating Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine. This coordinated reduction in hunger and food intake produces substantial, dose‑dependent weight loss Comparative Effectiveness of <scp>CagriSegma</scp> , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials+1.

Beyond its direct metabolic effects, tirzepatide appears to improve kidney outcomes largely by reducing new‑onset macroalbuminuria and slowing eGFR decline, likely through combined hemodynamic, anti‑inflammatory, and metabolic unloading mechanisms A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. In a mouse model of metabolic‑associated steatohepatitis, tirzepatide reduced liver steatosis and inflammatory signaling, pointing toward possible direct hepatic benefits Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis. Cardiovascular benefits probably emerge from the sum of weight loss, glucose lowering, blood pressure reduction, lipid improvement, and renal protection, although dedicated outcome data are still maturing Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis+1.

Tirzepatide was designed for once‑weekly dosing by attaching a fatty‑diacid chain that promotes albumin binding, giving it a half‑life of about 5 days. Steady‑state levels are reached after roughly 4 weeks. Gastric‑emptying delay is strongest early in treatment; appetite suppression persists longer Tirzepatide: First Approval+1.

Glycemic control. In type 2 diabetes, tirzepatide reliably lowers HbA1c by roughly 2 percentage points from baseline, with effects sustained over 40 weeks or more. The response is dose‑dependent, but glycemic benefit tends to plateau at higher doses Tirzepatide: First Approval+2.

Weight loss. Obesity trials and network meta‑analyses document placebo‑adjusted weight reductions of about 18% at 15 mg, with a substantial proportion of participants achieving ≥10% and ≥15% loss. Real‑world studies mirror these results, though absolute losses are often smaller because many users remain on lower doses Comparative Effectiveness of <scp>CagriSegma</scp> , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials+1. Compared head‑to‑head with semaglutide, tirzepatide consistently yields greater weight loss — for example, 14.7% vs. 10.8% over two years in a matched observational study, and nearly double the rate of ≥15% loss in the first year Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study+1.

Kidney protection. In exploratory analyses from the SURPASS‑CVOT trial, tirzepatide reduced a composite kidney outcome by 23% compared with dulaglutide, driven mainly by fewer cases of persistent macroalbuminuria and a slower decline in eGFR. The benefit was larger in patients with higher‑risk chronic kidney disease A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial.

Cardiometabolic improvements. Beyond weight and glucose, tirzepatide improves several cardiometabolic risk markers. In a 24‑week real‑world cohort with obesity and psoriasis, LDL‑C fell 6.7%, triglycerides 15.4%, and liver enzymes declined by 11–12% Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study. Pooled analyses suggest cardiovascular benefit signals, including favorable trends in major adverse cardiovascular events and heart failure, though the evidence is less definitive than for semaglutide Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.

Additional areas. Observational studies and early trials support benefits in obstructive sleep apnea (FDA‑approved for this indication), metabolic‑associated liver disease, and psoriasis with obesity. The evidence level varies from moderate to low‑moderate Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study+3. Data on post‑bariatric weight regain and use in type 1 diabetes are limited but emerging Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety+1.

All published research protocols use once‑weekly subcutaneous injections. The dose is not adjusted for body weight; fixed‑dose escalation is the standard Tirzepatide: First Approval+2.

Representative escalation schedule

Research protocols typically start with 2.5 mg once weekly for 4 weeks to allow the body to adjust and limit gastrointestinal side effects. This is not a maintenance dose. The first maintenance step is 5 mg once weekly, usually continued for at least 4 weeks Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). Further increases of 2.5 mg every 4 weeks (to 7.5 mg, 10 mg, 12.5 mg, and 15 mg) are made only if tolerated and if additional glycemic or weight‑loss benefit is needed Comparative Effectiveness of <scp>CagriSegma</scp> , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials. Many real‑world users achieve substantial weight loss without reaching the maximum dose Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study.

Initiation and titration rationale

The slow escalation minimizes the nausea, constipation, and low appetite that are most common during the first 4–8 weeks after starting or after a dose increase. If side effects are bothersome, protocols often pause escalation or hold the current dose for several weeks before trying the next step. Community practice frequently extends the time at each dose beyond the standard 4‑week interval when tolerance is poor Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)+1.

Intake and injection timing

Research does not mandate a specific time of day or relation to meals. However, practitioners often suggest administering the injection on a day when food intake is lighter to reduce nausea. Avoiding very large or high‑fat meals around injection day can help, but this advice comes from practical experience rather than controlled studies Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO). There is no evidence supporting intramuscular or oral use; the only studied route is subcutaneous Tirzepatide: First Approval+1.

Duration and chronic use

Tirzepatide is studied as a long‑term, continuous therapy. In clinical trials and real‑world datasets, weight loss and metabolic improvements are sustained with ongoing treatment, while discontinuation reliably leads to partial regain Six-Month Real-World Effectiveness, Persistence and Safety of Low-to-Moderate Dose Tirzepatide in Adults With Obesity: A Multicentre Observational Study+1. Short‑term “cycles” are not supported by clinical evidence. For a visual overview of a representative protocol, refer to the timeline above.

In approved clinical use, tirzepatide is supplied as a ready‑to‑use single‑dose pen or auto‑injector that requires no reconstitution Tirzepatide: First Approval+1. When research‑grade lyophilized tirzepatide is used, it must be reconstituted with an appropriate diluent before injection. This process is performed by the researcher and differs from the handling of commercial products.

Reconstitution steps (for lyophilized material only)

• Use bacteriostatic water (0.9% benzyl alcohol) for multi‑dose vials or sterile water for single‑use preparation.
• Add diluent gently down the vial wall, swirl to dissolve, and never shake the vial because agitation can damage the peptide.
• Aim for a final concentration that allows accurate measurement of small doses; 5 mg/mL is a common practical target.

Storage and stability

• Unreconstituted powder: Store at 2–8°C (refrigerated) and protect from light and moisture. For longer storage, –20°C is acceptable.
• Reconstituted solution: Keep at 2–8°C upright and protected from light. Do not freeze. When reconstituted with bacteriostatic water, discard after 28–30 days. With sterile water only, discard after 24–72 hours.
• Inspect the solution before each use. If it becomes cloudy, develops particles, or changes color, discard it. Label each vial with the concentration, date of reconstitution, and discard date to prevent dosing errors.

Use the interactive reconstitution calculator below to determine diluent volumes and resulting concentrations for specific vial sizes.

Tirzepatide’s main pharmacological effects—delayed gastric emptying, appetite suppression, and glucose lowering—drive most clinically relevant interactions. It does not heavily rely on CYP‑450 liver enzymes for metabolism Tirzepatide: First Approval+1.

Glucose‑lowering medications

When tirzepatide is added to insulin, sulfonylureas, or meglitinides, the risk of low blood glucose rises even though tirzepatide alone rarely causes hypoglycemia. Research protocols typically reduce the background insulin or secretagogue dose at the start and during escalation, with frequent glucose monitoring for the first few weeks Tirzepatide: First Approval.

Oral medications affected by slowed stomach emptying

Delayed gastric emptying is most pronounced in the first 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. This can alter the absorption of oral drugs that require predictable timing or a narrow therapeutic window.

• Oral contraceptives: Absorption may be reduced, raising the risk of unintended pregnancy. Backup non‑oral contraception (e.g., IUD, implant, ring) is recommended for 4 weeks after initiation and for 4 weeks after each dose escalation THU255 Tirzepatide-induced Weight Loss In A Type 2 Diabetic Taking Oral Contraceptives.
• Levothyroxine: TSH may fall early in treatment, likely from altered absorption and weight‑related physiology. Recheck TSH 4–8 weeks after starting or after major dose changes; some patients need a dose reduction Levothyroxine sodium/Tirzepatide+1.
• Lithium: Dehydration and reduced renal clearance can precipitate toxicity. Case reports describe lithium toxicity requiring hemodialysis; frequent monitoring of lithium levels and kidney function is advised, especially during dose increases or gastrointestinal illness Tirzepatide-Associated Lithium Toxicity Necessitating Hemodialysis in Previously Stable Bipolar I Disorder.
• Warfarin and other narrow‑therapeutic‑index drugs: Formal studies are lacking, but absorption variability is possible. Increase INR monitoring during initiation and dose changes A Case of Pulmonary Hemorrhage, Supratherapeutic International Normalized Ratio (INR), and Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: Unmasking a Potential Link to Tirzepatide.

Drugs that worsen dehydration or constipation

Combining tirzepatide with diuretics, RAAS blockers, or NSAIDs adds to the risk of volume depletion and acute kidney injury when gastrointestinal side effects are severe. Hold or reduce diuretics temporarily during vomiting or diarrhea, and monitor creatinine Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study+1. Opioids, anticholinergics, and other constipation‑promoting drugs increase the risk of severe constipation, gastroparesis‑like symptoms, or bowel obstruction. Start a bowel regimen early if baseline constipation exists, and pause tirzepatide if bowel movements drop sharply Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study+2.

Psychiatric and ophthalmologic considerations

Pharmacovigilance signals suggest a possible increase in depressed mood and suicidal thoughts, particularly in patients with pre‑existing affective disorders; monitor closely when combining with antidepressants Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study. A rare signal for optic ischemic neuropathy has been reported; counsel patients to seek urgent evaluation for sudden vision loss Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.

In research, tirzepatide is intended for continuous, long‑term use. The clinical evidence shows that its metabolic benefits are sustained only while the drug is active, and that stopping leads to significant weight regain Weight maintenance after discontinuation of GLP-1 therapies+1. Randomized trials and real‑world data therefore do not support planned on‑off cycles; rather, they favor dose management and slow titration to maintain tolerability.

When a temporary break may be considered

Community protocols sometimes pause tirzepatide for a few reasons, but these are driven by pragmatics, not efficacy data:

• Intolerable side effects despite holding the dose or stepping down.
• Cost or access interruptions.
• Preparation for surgery or procedures that require general anesthesia (because of delayed gastric‑emptying concerns).
• Pregnancy planning. In such cases, the approach is usually to stop the drug, not to cycle.

How to manage a break

If a break is necessary, practitioners often recommend stepping down gradually rather than stopping abruptly—for example, reducing from 10 mg to 7.5 mg for a few weeks before a full stop—to smooth appetite rebound. During any off period, increased focus on dietary protein, resistance exercise, and behavioral support helps limit regain Weight maintenance after discontinuation of GLP-1 therapies.

Restarting after a gap

After more than a few weeks off, gastrointestinal tolerance often resets. Most protocols restart at 2.5 mg and titrate up again, even if the previous dose was much higher, because jumping back to a high dose can cause severe nausea Weight maintenance after discontinuation of GLP-1 therapies.

No evidence for “cycling” to improve efficacy

There is no human evidence that taking breaks improves long‑term weight loss, resensitizes receptors, or prevents tolerance. Steady‑state receptor engagement is the basis of tirzepatide’s design. Rapid weight regain after discontinuation argues strongly against routine cycling Weight maintenance after discontinuation of GLP-1 therapies+1.

Stacking tirzepatide with other compounds is not well studied in controlled trials, and most available information comes from mechanistic reasoning, pharmacovigilance, and small case series.

With other GLP‑1 receptor agonists (e.g., semaglutide, liraglutide)

These agents overlap heavily in mechanism—delayed gastric emptying, appetite suppression, and incretin signaling. Combining them is expected to intensify gastrointestinal side effects without an evidence‑based benefit. Standard clinical practice is to switch, not stack Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus+1.

With amylin analogs (e.g., cagrilintide)

Amylin analogs reduce food intake partly through different central pathways and by slowing gastric emptying. There is theoretical synergy for weight loss, but this also amplifies nausea and constipation. If explored in a research setting, starting doses for both drugs should be very low and titration extremely slow Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.

With growth hormone secretagogues or anabolic peptides

Tirzepatide promotes weight loss, which includes some lean body mass. Combining it with agents that aim to preserve or build muscle (e.g., apitegromab, studied in a phase 2 trial Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial) is an area of active investigation. Outside of formal trials, stacking anabolic peptides with tirzepatide raises competing signals: the appetite‑suppressing effect may make it difficult to eat enough to support muscle growth. The best‑studied approach for lean‑mass preservation during tirzepatide therapy remains adequate protein intake and resistance training Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.

General precaution

Do not start tirzepatide at the same time as another new appetite‑suppressing peptide or significant dose change in another drug; introduce one variable at a time so that any intolerance can be clearly attributed. Always monitor blood glucose closely when combining glucose‑lowering agents.

Tirzepatide is FDA‑approved for three indications in the United States Tirzepatide (Zepbound) for chronic weight management+2:

• Type 2 diabetes (brand name Mounjaro, since 2022)
• Chronic weight management (brand name Zepbound, since 2023) in adults with obesity or with overweight and at least one weight‑related comorbidity
• Moderate‑to‑severe obstructive sleep apnea in adults with obesity (Zepbound, 2024)

It is not a controlled substance and not currently listed in any DEA schedule. The FDA has issued post‑marketing warnings about rare reports of pulmonary aspiration during general anesthesia or deep sedation in patients taking GLP‑1 receptor agonists, including tirzepatide, because delayed gastric emptying can leave residual stomach contents In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists.

In the UK, tirzepatide is licensed for type 2 diabetes and weight management. NICE initially issued draft guidance not recommending it, but later published final draft guidance recommending it for type 2 diabetes NICE recommends tirzepatide for type 2 diabetes in final draft guidance+1. A large pragmatic trial (SURMOUNT‑REAL UK) is evaluating its real‑world obesity effectiveness in UK primary care <scp>SURMOUNT</scp> ‐ <scp>REAL UK</scp> : A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity. Other countries, including Switzerland, include tirzepatide in obesity clinical practice guidance Swiss obesity clinical practice guidance.

WADA / anti‑doping status: No corpus source addresses WADA status. Athletes are advised to check the current WADA Prohibited List for any updates, as anti‑doping rules can change annually.

Common adverse effects

Gastrointestinal events are the most frequent side effects reported in trials and real‑world use. Nausea, constipation, diarrhea, vomiting, and abdominal discomfort occur in many users, especially during the first weeks and after dose increases. In a 24‑week observational study using 2.5 mg titrated to 5 mg, constipation occurred in 25%, nausea in 12%, and diarrhea in 4%. No participant stopped treatment because of side effects Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study. Most GI effects are mild to moderate and improve over time Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)+2.

Less common but serious events

• Severe gastrointestinal dysmotility: Compared with SGLT2 inhibitors, GLP‑1‑based therapies including tirzepatide are associated with a higher risk of severe constipation, gastroparesis, and gastrointestinal obstruction, though the absolute risk remains low (about 1 per 100 person‑years) Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. Case reports describe small‑bowel obstruction in patients with and without prior bowel surgery Severe Small-Bowel Obstruction in a High-Risk Patient on Long-Term Tirzepatide Therapy: A Case Report+1.
• Gallbladder and pancreatic events: Acute pancreatitis has been reported after starting tirzepatide, often in the presence of gallstones or other risk factors. The absolute incidence is low A Probable Case of Tirzepatide-Induced Acute Pancreatitis+2.
• Ketoacidosis‑spectrum events: Rare but serious. Pharmacovigilance analysis shows a strong signal for starvation ketoacidosis, with additional reports of euglycemic diabetic ketoacidosis (DKA) in patients not using SGLT2 inhibitors. These events typically occur during marked calorie restriction, vomiting, or abrupt insulin reduction Disproportionality Analysis of Tirzepatide-Associated Ketoacidosis+2.
• Hair loss: A recognized but usually non‑severe signal. Tirzepatide shows one of the strongest alopecia signals among GLP‑1‑based agents in pharmacovigilance databases, most consistent with telogen effluvium triggered by rapid weight loss and nutritional stress Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes+2.
• Renal injury: Acute kidney injury can occur secondary to dehydration from severe GI losses. Case reports document reversible acute renal failure after prolonged vomiting and diarrhea 7529 A Silent Menace Of Mounjaro: Acute Renal Failure Associated With Tirzepatide.
• Hypersensitivity: Rare injection‑site reactions and generalized urticaria have been reported A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide+1.
• Neuropsychiatric effects: Low‑frequency signals for depressed mood, suicidal thoughts, and a case of dysphoria/aggression have been noted; confounding by underlying conditions is substantial A Case of GLP-1 Receptor Agonist-Induced Dysphoria and Aggression in a Patient With Underlying Major Depressive Disorder+1.
• Optic ischemic neuropathy: A rare post‑marketing signal; causality is not established Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.

Contraindications and precautions

Absolute contraindications include prior serious hypersensitivity to tirzepatide or its excipients and personal/family history of medullary thyroid carcinoma or MEN2. Active pancreatitis is a contraindication until fully resolved, and rechallenge is generally avoided after probable drug‑related pancreatitis A Probable Case of Tirzepatide-Induced Acute Pancreatitis+1.

Relative contraindications where extreme caution is warranted: prior gastroparesis, chronic severe constipation, bowel obstruction, or extensive abdominal adhesions; active eating disorder or severe caloric restriction; gallstones or heavy alcohol use; CKD with poor oral intake tolerance; and significant depressive disorder or recent suicidal ideation Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study+4.

Monitoring recommendations

Before starting, baseline weight, blood pressure, hydration status, HbA1c, fasting glucose, renal function, and liver enzymes are recommended. TSH should be checked if taking levothyroxine. During titration, close monitoring of gastrointestinal symptoms, weight‑loss velocity, and renal function/electrolytes is advised, especially if GI side effects develop. For patients using oral contraceptives, barrier or non‑oral methods are recommended for the first 4 weeks and for 4 weeks after each dose increase THU255 Tirzepatide-induced Weight Loss In A Type 2 Diabetic Taking Oral Contraceptives. Before procedures requiring general anesthesia, the delayed gastric‑emptying effect should be considered because of aspiration risk In brief: New FDA warning of pulmonary aspiration with GLP-1 receptor agonists.

Red flags that warrant holding the drug and seeking immediate evaluation include persistent severe abdominal pain, bilious vomiting, inability to keep down fluids, signs of bowel obstruction, symptomatic ketosis, or sudden vision loss.